Using the cell line and Gαgust−/− mice, we investigated the cellular mechanism underlying the GLP-1 secreting effect of Rg3, and using db/db mice, we evaluated the possibility of exploiting the effect of Rg3 as a therapeutic agent for type 2 diabetes mellitus. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.